Latest close
$560.36
As of Oct 16, 2026
| Fund | Portfolio weight | Shares | Change vs prev. quarter |
|---|---|---|---|
| Fundsmith | 3.93% | 1,019,887 | TRIMMED (-30.4%) |
| Montrusco Bolton Investments | 3.04% | 372,788 | ADDED (+9.0%) |
| Polen Capital Management | 2.41% | 532,384 | TRIMMED (-23.5%) |
| Jensen Investment Management | 1.35% | 105,709 | ADDED (+2861.0%) |
| Weitz Investment Management | 1.29% | 35,300 | HELD |
| Flossbach von Storch | 0.04% | 17,270 | TRIMMED (-4.2%) |
| Mairs & Power Funds | 0.01% | 2,080 | HELD |
| Oakmark Funds | <0.01% | 455 | TRIMMED (-5.6%) |
Source: SEC Form 13F filings for the quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. 13F filings cover long positions only and arrive up to 45 days after quarter-end. Fund counts here aggregate every share class mapped to this ticker; research headlines cite filer counts as they stood at publication, so a count here can differ from a headline by a holder (see Methodology, "How holder counts are counted").
Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.
| Institutions holding | 1,285 of 8,857 filers |
| Long-only filers among them | 1,284 |
| Change vs 2026 Q1 | no net change · 1,096 entered · 1,096 exited |
| Shares reported, all filers | 73,107,956 |
| Reported value, all filers | $37.6B |
Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).
| Exchange | Nasdaq |
| Industry | In Vitro & In Vivo Diagnostic Substances (SIC 2835) |
| Revenue · FY2025 | $4.3B |
| Net income · FY2025 | $1.1B |
| Total assets · FY2025 | $3.4B |
| Shares outstanding | 78,781,116 |
| Market cap (at latest close) | $44.1B |
Source: SEC EDGAR company filings (submissions and company facts), collected Oct 7, 2026. Shares outstanding as reported Jul 31, 2026.
| Shares short · Sep 15, 2026 | 1,917,016 |
| Share of shares outstanding | 2.43% |
| Days to cover | 3.77 |
Shares short at recent settlements — Jun 30, 2026: 1.9M · Jul 15, 2026: 2.1M · Jul 31, 2026: 1.9M · Aug 14, 2026: 1.9M · Aug 31, 2026: 2.1M · Sep 15, 2026: 1.9M.
Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Jul 31, 2026.
| Shares failed to deliver · Sep 15, 2026 | 0 |
| Share of shares outstanding | 0.00% |
| Fails as a share of short interest · Sep 15, 2026 | 0.0% |
Fails to deliver at recent settlements — Jun 30, 2026: 0 · Jul 15, 2026: 0 · Jul 31, 2026: 0 · Aug 14, 2026: 0 · Aug 31, 2026: 0 · Sep 15, 2026: 0.
Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Jul 31, 2026.
0 insiders bought on the open market in the last 90 days (0 purchases, $0), against 1 sale by 1 insider ($1.2M).
Source: SEC Form 4 filings, as of Oct 17, 2026. Open-market transactions only.
Data unavailable — no congressional STOCK Act transactions for this ticker were parsed in the current window (as of Oct 3, 2026).
Financial Screens
· Buffett — Companies with high ROE sustained for more than a decade
· Growth — Revenue up every year for 5 straight years
· Piotroski — Financial health improved over the past year
· Gross Profitability (Novy-Marx) — High gross profit relative to total assets
· Earnings Quality (Cash Conversion) — Profits that actually come back as cash
· Earnings Stability — Small earnings swings and almost no loss years
Key figures
· Buffett — Latest ROE: 56.9% · Years ROE ≥15% (of 10): 10 · 10-yr avg ROE: 88.2% · Latest net income: $845.0M
· Growth — Latest revenue: $4.3B · 5-yr revenue CAGR: 9.7% · Straight growth years: 9
· Piotroski — F-score: 7 · Return on assets: 31.6% · Operating cash flow: $1.2B
· Gross Profitability (Novy-Marx) — Gross profit / assets: 79.4% · Gross margin: 61.8%
· Earnings Quality (Cash Conversion) — Cash conversion (3-yr avg): 1.08 · Operating cash flow: $1.2B · Net income: $1.1B
· Earnings Stability — Earnings variation (CV): 0.44 · Loss years (of 10): 0 · Latest net income: $1.1B
Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.
· Politician BEST — appeared in 1 of the last 20 quarterly lists; latest 2025 Q2, ranked #32 of 50.
| 13F signal (2021 Q3 – 2026 Q1) | Events | Win rate | Avg return | SPY | Excess |
|---|---|---|---|---|---|
| Heavy accumulation — 3+ tracked funds increased together | 7 | 42.9% | -1.1% | +3.3% | -4.5% |
Measured from SEC 13F filings: entry at the close on the first trading day after each quarter’s filing deadline, exit one quarter later on the same rule, dividend-adjusted closes. Past records do not guarantee future results — see Track Record and Methodology.
Also held by the tracked funds that hold IDXX: MICROSOFT CORP (MSFT) · Meta Platforms, Inc. (META) · Mastercard Inc (MA) · AMAZON COM INC (AMZN) · Alphabet Inc. (GOOGL) · TAIWAN SEMICONDUCTOR MANUFACTURING CO LTD (TSM) · NVIDIA CORP (NVDA) · VISA INC. (V) · Apple Inc. (AAPL) · Broadcom Inc. (AVGO).
Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.